Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S,[1] develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Hørsholm, Denmark, with an office in Cary, North Carolina.[2]
MeltDose Technology Platform
MeltDose works by incorporating a drug substance with low water solubility into a "meltable" vehicle.[3] It is then sprayed on an inert particulate carrier using fluid bed equipment. The melt is solidified when deposed on a particle carrier, and thus captures the active drug in a solid dispersion either as a solid solution or in a nano-crystalline state. The particle size is then increased by controlling and optimizing the product temperature and feed rate of the melt. The granulate can be directly compressed into tablets without additional processing steps besides blending with a lubricant.